[ad_1]
Radnor, Pennsylvania, December 25, 2021 /PRNewswire/ – Law Firm Kessler Topaz Meltzer & Check, LLP Notify investors that they have received an interest in Organogenesis Holdings Inc. (“Organogenesis”) (Nasdaq stock code:Olgo). The lawsuit accuses Organogenesis of violating federal securities laws, including omissions and fraudulent misrepresentations related to the company’s business, operations, and prospects. Due to Organogenesis’s material misleading statements to the public, the investors of Organogenesis have suffered significant losses.
Check out our video, Please click here
click here Submit your organ production loss
Deadline for lead plaintiff: February 8, 2022
class time: March 17, 2021 pass through October 11, 2021
Contact a lawyer to discuss your rights:
James Marlow, Esq. (484) 270-1453 or free (844) 887-9500 or email to info@ktmc.com
Organogenic Suspected misconduct
Organogenesis is a regenerative medicine company that develops, manufactures and commercializes solutions for the advanced wound care, surgery and sports medicine markets. The company’s advanced wound care products include “Affinity,” an amniotic membrane allograft wound cover and surgical barrier used to care for chronic and acute wounds or surgical implants for spinal, orthopedic and sports medicine applications.
exist October 12, 2021, An anonymous report, VIC report, involving organogenesis published in Value Investor ClubThe report stated that Organogenesis has been…
The full story can be found on Benzinga.com
[ad_2]
Source link
